Adaptive Biotechnologies Corp (ADPT)vsThermo Fisher Scientific Inc (TMO)
ADPT
Adaptive Biotechnologies Corp
$16.90
-6.53%
HEALTHCARE · Cap: $2.82B
TMO
Thermo Fisher Scientific Inc
$472.80
-1.33%
HEALTHCARE · Cap: $179.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 15200% more annual revenue ($45.20B vs $295.41M). TMO leads profitability with a 15.1% profit margin vs -16.8%. TMO earns a higher WallStSmart Score of 62/100 (C+).
ADPT
Avoid30
out of 100
Grade: F
TMO
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.3%
Fair Value
$31.45
Current Price
$16.90
$14.55 discount
Margin of Safety
-41.7%
Fair Value
$331.35
Current Price
$472.80
$141.45 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.1% year-over-year
Large-cap with strong market position
Areas to Watch
Trading at 12.4x book value
0.0% earnings growth
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 35.1% demonstrates continued momentum.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.
Bear Case : ADPT
The primary concerns for ADPT are Price/Book, EPS Growth, Return on Equity.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ADPT profiles as a hypergrowth stock while TMO is a mature play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.15 — expect wider price swings.
ADPT is growing revenue faster at 35.1% — sustainability is the question.
TMO generates stronger free cash flow (816M), providing more financial flexibility.
Bottom Line
TMO scores higher overall (62/100 vs 30/100), backed by strong 15.1% margins. ADPT offers better value entry with a 50.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?